Skip to site menu Skip to page content

Daily Newsletter

17 October 2023

Daily Newsletter

17 October 2023

Aster Royal Al Raffah Multispecialty Hospital opens in Oman

The new hospital aims to serve Oman's five million citizens and international patients.

October 17 2023

Aster DM Healthcare has opened the Aster Royal Al Raffah Multispecialty Hospital, a 175-bed facility in Al Ghubra, Muscat, Oman, reported Zawya.

Inaugurated by Sayyid Fahar Bin Fatik Al Said, the hospital is said to feature the latest technology and specialised centres such as a Cath-lab for Advanced Cardiac Care and Interventional Radiology Centre.

Among other facilities are the Sports Medicine and Orthopedics Centre, Interventional Gastroenterology, Dialysis Unit with CRRT, and Neurosciences Centre.

Located 14 minutes from the international airport, it aims to serve Oman's five million citizens and international patients.

Aster DM Healthcare founder chairman and managing director Dr Azad Moopen was quoted by Zawya as saying: “Aster Royal Al Raffah Hospital in Al Ghubra, Muscat is a testament to our unwavering commitment to making world-class healthcare services available in Oman.

“We hope this shall help many patients from the Sultanate to avoid travelling overseas to seek advanced medical care.

“With our focus on many cutting-edge procedures to be done in the Aster Royal, we hope to raise the bar in healthcare excellence in the country.”

Aster DM Healthcare is a private healthcare provider in the GCC and India, offering primary, secondary, tertiary, and quaternary healthcare services.

The organisation operates 33 hospitals, 127 clinics, and 527 pharmacies, along with 229 labs in seven countries. It has a team of 31,222 staff, including 3,998 doctors and 9,204 nurses.

In addition, it delivers care to various economic segments, with a presence under the brand's Aster, Medcare, and Access.

AI will become a key driver of medical device innovation

With only a few approved drugs currently available to treat DN by means other than regulation of blood pressure, innovator products that can treat by targeting other factors such as treatment of dyslipidemia, hypertension, or angiotensin inhibition, among others, is a key area of R&D in the DN space and is likely to pave the way for novel therapies in the near future. However, the treatment landscape is expected to remain unchanged due to limited availability of products in the late-stage pipeline currently.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close